Nucleophosmin 1: from its pathogenic role to a tantalizing therapeutic target in acute myeloid leukemia

Shi, Yuye; Xue, Yuhao; Yu, Liang

doi:10.1080/16078454.2022.2067939

Cited by 6 publications

(1 citation statement)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been suggested that dysfunctional NPM1 may contribute to the development of AML by acting as a protein chaperone that prevents leukemia stem cells from differentiating and by regulating non-coding RNAs. In addition to traditional chemotherapy treatments, NPM1 shows promise as a target for AML therapy and should be further investigated [51], [52].…”

Section: Associated Genes/proteinsmentioning

confidence: 99%

Trending Drugs Combination to Target Leukemia associated Proteins/Genes: using Graph Neural Networks under the RAIN Protocol

Boush,

Kiaei,

Mahboubi

2023

Preprint

View full text Add to dashboard Cite

BackgroundLeukemia, a cancer impacting blood-forming tissues such as bone marrow and the lymphatic system, presents in various forms, affecting children and adults differently. The therapeutic approach is complex and depends on the specific leukemia type. Effective management is crucial as it disrupts normal blood cell production, increasing infection susceptibility. Treatments like chemotherapy can further weaken immunity. Thus, a patient’s healthcare plan should focus on comfort, reducing chemotherapy side effects, protecting veins, addressing complications, and offering educational and emotional support.MethodThis article reviews studies on the combined use of drugs for treating leukemia. Employing a mix of medicines might decrease the chances of tumor resistance. Starting multiple drugs concurrently allows for immediate application during disease onset, avoiding delays. Initial chemotherapy uses a drug combination to eliminate maximum leukemia cells and restore normal blood counts. Afterwards, intensification chemotherapy targets any residual, undetectable leukemia cells in the blood or bone marrow. To recommend a drug combination to treat/manage Leukemia, under first step of RAIN protocol, we have searched articles including related trend drugs using Natural Language Processing. In the second step, we have employed Graph Neural Network to pass information between these trending drugs and genes that act as potential targets for Leukemia.ResultAs a result, the Graph Neural network recommends combining Tretinoin, Asparaginase, and Cytarabine. The network meta-analysis confirmed the effectiveness of these drugs on associated genes.ConclusionThe p-value between leukemia and the scenario that includes combinations of the mentioned drugs is almost zero, indicating an improvement in leukemia treatment. Reviews of clinical trials on these medications support this claim.HighlightsCombined drugs that make p-value between Leukemia and target proteins/genes close to 1Using Graph Neural network to recommend drug combinationA Network meta-analysis to measure the comparative efficacyConsidered drug interactions

show abstract

Section: Associated Genes/proteinsmentioning

confidence: 99%